InvestorsHub Logo
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

Re: DanWebzster post# 407

Saturday, 12/19/2020 2:02:44 PM

Saturday, December 19, 2020 2:02:44 PM

Post# of 438
VIRI is a 12/20 IPO developing a Fibromyalgia treatment with an FDA Fasttrack designation.

A Ph2a POC study produced statistically significant data. This is the only program in their pipeline.

VIRI filed to raise 30M by offering 3 Million shares.

They burned $2.5M for the year in 2019.

A Ph2b study is planned to optimize a dose to be used in a Ph3 study for longer-term chronic usage.

The product is a combination of Famciclovir and Celecoxib.

The opty may be in the Billions.

Considering the questionable nature of many low-float stocks, this one seems to be a relatively attractive trading vehicle.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.